Oral Tablet Influenza Vaccine Shows Promising Results

influenza virus
influenza virus
An investigational H1 influenza oral tablet vaccine provides similar protection against influenza as an injectable vaccine.

An investigational H1 influenza oral tablet vaccine was found to provide similar protection against influenza as an injectable quadrivalent influenza vaccine (QIV) in a Phase 2 clinical trial. 

The trial participants were randomized to receive either a single dose of Vaxart oral tablet vaccine and a placebo intramuscular injection, a QIV injection plus a placebo tablet, or a double placebo. 

They were challenged intranasally with homologous A strain influenza virus 90–120 days after vaccination. Laboratory-confirmed homologous influenza A infections were compared among the groups. 

Results showed that the tablet vaccine provided a 39% reduction in clinical disease relative to placebo, compared to a 27% reduction with injectable QIV. The tablet also demonstrated a safety profile similar to placebo. 

“These results provide clinical proof-of-concept for Vaxart’s groundbreaking oral tablet vaccine technology,” said Wouter Latour, MD, MBA, CEO of Vaxart, in a press release. “A convenient and effective tablet vaccine could significantly increase current vaccination rates and generate important public health benefits for at-risk groups and the population as a whole.” 

Related Articles


Vaxart announces positive topline results for it oral tablet vaccine in phase 2 influenza challenge study [press release]. San Francisco, California: Vaxart. Published October 26, 2017. Accessed November 6, 2017.

This article originally appeared on MPR